Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF

Biotechnology Progress

Volumn 28, Issue 4, 2012, Pages 981-989

  Zhang, Juan ^a   Li, Haixin ^a   Wang, Xiuyun ^a   Qi, Haidi ^a   Miao, Xiaoniu ^a   Zhang, Tao ^a   Chen, Guosheng ^a   Wang, Min ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Phage display; Single chain antibody fragment (scFv); Vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

ANGIOGENESIS; BINDING AFFINITIES; BINDING ANALYSIS; CLINICAL APPLICATION; CLINICAL USE; EXTRACELLULAR DOMAINS; HUMAN ANTIBODIES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; KINETIC DETERMINATION; MOLECULAR DOCKING; PHAGE DISPLAY; SEQUENCE ANALYSIS; SINGLE-CHAIN ANTIBODIES; THERAPEUTIC ANTIBODIES; TUMOR ANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR-2;

BINDING ENERGY; BIOSENSORS; DIAGNOSIS; ENDOTHELIAL CELLS;

ANTIBODIES;

SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

AMINO ACID SEQUENCE; ARTICLE; BACTERIOPHAGE; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; GENETICS; HUMAN; IMMUNOLOGY; KINETICS; METABOLISM; MOLECULAR GENETICS; PEPTIDE LIBRARY; PROTEIN TERTIARY STRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINO ACID SEQUENCE; BACTERIOPHAGES; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; SINGLE-CHAIN ANTIBODIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84864858734     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1559     Document Type: Article

References (30)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-31.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23: 1011-1027.
3. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005; 94:209-231.
4. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25-35.
5. Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, Wedge SR, Blakey DC, Foltz I, Zhou J, Kang JS, Barry ST. An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding. Mol Cancer Ther. 2011; 10: 770-783.
6. Erdag B, Balcioglu BK, Bahadir AO, Serhatli M, Kacar O, Bahar A, Seker UO, Akgun E, Ozkan A, Kilic T, Tamerler C, Baysal K. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2. Biotechnol Appl Biochem. 2011; 58: 412-422.
7. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol. 2010; 6: 1085-1094.
8. Ton NC, Parker GJ, Jackson A, Mullamitha S, Buonaccorsi GA, Roberts C, Watson Y, Davies K, Cheung S, Hope L, Power F, Lawrance J, Valle J, Saunders M, Felix R, Soranson JA, Rolfe L, Zinkewich-Peotti K, Jayson GC. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007; 13: 7113-7118.
9. Bruce D, Tan PH. Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? Expert Opin Investig Drugs. 2011; 20: 1413-1434.
10. Planchard D. Bevacizumab in non-small-cell lung cancer: a review. Expert Rev Anticancer Ther. 2011; 11: 1163-1179.
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
13. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6: 2012-2021.
14. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26: 2013-2019.
15. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-4740.
16. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29: 3968-3976.
17. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005; 69(Suppl 3): 25-33.
18. Fuh G, Li B, Crowley C, Cunningham B, Wells JA. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem. 1998; 273: 11197-11204.
19. Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J Biol Chem. 2000; 275: 14321-14330.
20. Zhang J, Li H, Chen W, Cao P, Wang M. Preparation of extracellular domain 3 of human VEGF receptor-2 and the monitoring of its real-time binding to VEGF by biosensors. Biotechnol Prog. 2009; 25: 1703-1708.
21. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991; 222: 581-597.
22. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, Prospero TD, Hoogenboom HR, Nissim A, Coxl JPL, Harrison JL, Zaccolo M, Gherardi E, Winter G. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994; 13: 3245-3260.
23. Sambrook J, Russell DW, Molecular Cloning: A Laboratory Manual, 3rd ed. New York: Cold Spring Harbour Laboratory Press (2001).
24. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994; 22: 4673-4680.
25. Westbrook J, Feng Z, Chen L, Yang H, Berman HM. The Protein Data Bank and structural genomics. Nucleic Acids Res. 2003; 31: 489-91.
26. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006; 22: 195-201.
27. Arcangeli C, Cantale C, Galeffi P, Rosato V. Structure and dynamics of the anti-AMCV scFv(F8): effects of selected mutations on the antigen combining site. J Struct Biol. 2008; 164: 119-133.
28. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004; 32: W96-W99.
29. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003; 52: 80-87.
30. WL D, The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA, available at http://www.pymol.org: 2010.